Lytix Biopharma (Norway) pre-clinical developer of lytic peptide drugs for the treatment of resistant bacterial, fungal infections and tumor progression, closed a $10.4M Series D financing.
Participants in financings have included Picasso Kapital, Såkorninvest Nord, Norinnova, Sparebanken Nord-Norge Invest, Serepta, Rekdal, Svendsen, Norinnova Invest and Taj Holding.